First AD

Second AD

Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

HER2 Alterations in Non-Small Cell Lung Cancer

Peer Exchange

Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.

Testing Patients with NSCLC for HER2 Mutations

Biomarker Testing in NSCLC: Clinical Scenario

Approaches to Biomarker Testing in NSCLC

Liquid vs Solid Tumor Biopsies in NSCLC

HER2 Alterations in NSCLC: Clinical Scenario

The Role of HER2 Alterations in NSCLC

Current Treatment Options in NSCLC

Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

HER2-Targeted Therapies in NSCLC

Major Adverse Events of Anti-HER2 Therapies

Unmet Needs in NSCLC Therapy

Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

Novel HER2-Targeted Therapies for NSCLC